Godavari Drugs is a contract manufacturer of active pharmaceutical ingredients - the molecules that give medicines their effect - built on a single, integrated factory in Nanded, Maharashtra, where it has spent 37 years turning complex chemistry into commercial-scale production. The company was founded in 1987 and has grown from a domestic supplier into an exporter to 23 countries by combining deep process-engineering skills with a willingness to make what its customers need, whether under its own label or theirs. The recurring approach is to own the entire chain from laboratory idea to finished kilogram, so that a pharmaceutical partner can hand over a molecule and get back a validated, scalable manufacturing process without ever touching a reactor. # Business segments A single engine - contract and own-label manufacturing of active pharmaceutical ingredients and their intermediates - where the same factory, the same chemists and the same quality systems serve both sides of the business. ## 1. API and intermediate manufacturing: the molecule factory **The company makes the active chemical ingredients inside medicines - both its own products and, increasingly, other companies' products under contract - using one integrated plant that can take a process from a chemist's bench to a commercial batch.** - **Own-label generics anchor the portfolio** - the company manufactures and sells a focused range of APIs under its own name, concentrated in quinolone antibacterials (Ciprofloxacin and its variants for human use, Enrofloxacin for veterinary use), anticonvulsants (Carbamazepine), and anti-inflammatory drugs (Mefenamic Acid), which gives it a steady base of repeat orders from generic-drug formulators. - **Contract manufacturing opens the door to multinationals** - it offers loan-license and contract manufacturing services, meaning a large pharma company can bring a molecule, and Godavari Drugs will develop the process, scale it up in its pilot plant, and run commercial production under the partner's regulatory filings, all inside a facility that meets cGMP (current Good Manufacturing Practice) standards. - **Narcotic capability is a rare permission** - the company is licensed to manufacture narcotic drugs and offers that capacity on a contract basis to partners, a niche that few Indian API manufacturers can serve because of the regulatory hurdles involved. - **Backward integration locks in supply** - it has been pushing upstream into making its own intermediates, the chemical building blocks that feed API production, so that it is less exposed to the price swings and delivery risks of imported raw materials, which in some years have accounted for more than three-quarters of its input bill. - **Export reach spans 23 countries** - the customer list stretches across the Middle East, Africa, Southeast Asia and Latin America, from Egypt and Iraq to Vietnam and Paraguay, giving it a diversified order book that partly hedges the foreign-exchange cost of the raw materials it still imports. # The manufacturing backbone: one site, every step **The Nanded plant is a self-contained industrial chemistry campus - reactors, clean rooms, quality labs, a pilot plant and a zero-discharge effluent system all sit inside the same gate, so nothing leaves the site until it is a finished, tested API.** - **Multiple production blocks under one roof** - the facility inside the MIDC industrial estate at Nanded houses separate blocks for different APIs and intermediates, each built to cGMP requirements, with dedicated clean rooms classified for the specific handling needs of each product. - **Quality control is in-house and immediate** - five separate laboratories handle raw-material testing, in-process checks, finished-product analysis, instrumentation and stability studies, meaning a batch never waits for an outside lab to confirm it is right. - **The pilot plant doubles as a small-batch factory** - equipped with hydrogenators, vapour-phase catalytic-bed reactors and stainless-steel vessels, the pilot plant scales processes from grams to kilograms and can also run commercial production of low-volume, high-value products, which is how the company takes on niche molecules that bigger plants would ignore. - **Zero Liquid Discharge means the site cleans up after itself** - a full-fledged effluent treatment plant inside the premises treats all process water so that nothing leaves the site as untreated waste, a requirement that is increasingly non-negotiable for multinational partners auditing a supplier's environmental compliance. - **A second facility is under construction** - the company is building a new, automation-heavy API and intermediate plant designed to global regulatory standards on 17.5 acres of newly allotted land in MIDC Krushnoor, also in Nanded district, with commissioning expected towards the end of the current financial year, which will expand capacity and add the kind of automated, continuous-process equipment that regulators and large customers now prefer. # R&D and process technology: from lab bench to reactor **The company's research team does not just invent new molecules - it invents the manufacturing route, figuring out how to make a given API cheaper, cleaner and without infringing existing patents, then proves the process works at kilogram scale before it ever touches a commercial reactor.** - **Chemistry plus engineering is the core formula** - the company describes its strength as the combination of intrinsic chemistry knowledge with "extremely sound engineering strengths" and analytical backup, which means it can develop a synthesis route in the lab and then design the actual reactors, pipes and controls to run it at scale. - **Green chemistry and non-infringing processes are the selling point** - the R&D team focuses on cost-effective synthesis that avoids patented routes and uses greener solvents and conditions, because a generic-drug customer needs a process that is both legal to use and cheap enough to compete. - **Flow chemistry and continuous processing are already in place** - the company has adopted flow-chemistry techniques and automated continuous manufacturing, which replace traditional batch processing with a steady, controlled stream of reactants, improving consistency and safety while reducing solvent use. - **The kilo lab bridges the gap between beaker and batch** - a state-of-the-art, fully automated kilo-lab facility handles a wide range of chemical reactions at the one-to-ten-kilogram scale, generating the data and the sample quantities that a commercial partner needs before committing to a full production campaign. # Group structure and partners **Godavari Drugs is a standalone, promoter-led company with no subsidiaries or joint ventures - it operates a single factory, sells to the world, and is funded by two Indian banks and a recent equity raise from its founding families and outside investors.** - **No corporate web** - the company has no subsidiaries, associates or joint ventures, so all operations, assets and cash flows sit inside one listed entity, simplifying both governance and credit analysis. - **Promoter families hold just over half** - as of March 2025, promoters owned 52.63% of the equity, and a preferential issue of shares and convertible warrants approved in early 2026 to nine promoter-group individuals and 31 outside investors (including a fund) would leave the promoters at 51.52% on a fully diluted basis after conversion. - **Two bankers, no complexity** - the company's banking relationships are with Yes Bank and ICICI Bank, a straightforward structure for a business of this scale. - **Leadership is stable and technical** - the Managing Director, a chemical engineer with more than 40 years in the industry, has run operations since the company was founded, while the Whole-Time Director and CFO, an engineer with over 30 years of experience, handles technical activities, marketing, finance and compliance, creating a management layer that understands both the chemistry and the commercial side.